Oral PRI-002 treatment in patients with MCI or mild AD: a randomized, double-blind phase 1b trial

Oral PRI-002 treatment in patients with MCI or mild AD: a randomized, double-blind phase 1b trial

Abstract Self-replicating amyloid beta (Aβ) oligomers are considered as one of the major drivers for disrupted synaptic function and plasticity, leading to impaired neuronal viability and progression of Alzheimer’s disease (AD). Here, we investigated the safety, tolerability and pharmacokinetics of...

Full description

Saved in:
Bibliographic Details
Main Authors: Janine Kutzsche, Nicoleta Carmen Cosma, Gunther Kauselmann, Friederike Fenski, Christine Bieniek, Tuyen Bujnicki, Marlene Pils, Oliver Bannach, Dieter Willbold, Oliver Peters
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-59295-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-025-59295-z

Similar Items